VERAXA Biotech AG, a portfolio company of Xlife Sciences AG (SIX: XLS), has secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement with Lincoln Park Capital Fund LLC, providing access to up to $50 million in equity financing. The financing arrangements are intended to strengthen VERAXA’s financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market.
The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share. The equity line with Lincoln Park Capital provides VERAXA with discretionary access to capital over a 24-month period without warrants or participation rights. The company said the combined financing structure supports continued development of its antibody-based therapeutic pipeline, including proprietary BiTAC formats and antibody-drug conjugates.
This news matters because it signals a significant step for VERAXA as it prepares to enter the public market, potentially providing the capital needed to advance its drug discovery and development engine. The financing from High Trail Capital and Lincoln Park Capital not only bolsters VERAXA’s balance sheet but also demonstrates investor confidence in its technology platform, which originates from scientific discoveries at the European Molecular Biology Laboratory (EMBL). For the biotechnology industry, this move highlights the ongoing trend of private biotech firms seeking public listings to fund clinical development, particularly in the competitive antibody-drug conjugate space.
The implications for VERAXA are substantial: the $27.5 million convertible note provides immediate working capital, while the $50 million equity line offers flexibility to raise additional funds over two years without dilutive warrants. This structure allows VERAXA to focus on its pipeline without the pressure of immediate capital constraints. For investors, the terms—including the $11.50 warrant exercise price—provide a potential upside if the company’s stock performs well post-listing.
VERAXA Biotech AG aims to establish a premier drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. The company applies quality-by-design principles in drug discovery, accelerating its pipeline of antibody drug conjugates and BiTAC antibody formats into and through clinical development. Xlife Sciences, as an incubator and accelerator, focuses on value development and commercialization of promising research projects from universities and research institutions in the life sciences sector, aiming to provide solutions for high unmet medical needs.
For more information, visit the full press release at https://ibn.fm/oxUOU or VERAXA’s website at https://www.veraxa.com/.
